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A B S T R A C T
Receptor tyrosine kinase (RTK)-mediated hyperactivation of the MAPK/Erk pathway is responsible for a large
number of pathogenic outcomes including many cancers. Considerable effort has been directed at targeting this
pathway with varying degrees of long term therapeutic success. Under non-stimulated conditions Erk is bound to
the adaptor protein Shc preventing aberrant signalling by sequestering Erk from activation by Mek. Activated
RTK recruits Shc, via its phosphotyrosine binding (PTB) domain (ShcPTB), precipitating the release of Erk to
engage in a signalling response. Here we describe a novel approach to inhibition of MAP kinase signal trans-
duction through attempting to preserve the Shc-Erk complex under conditions of activated receptor. A library of
existing drug molecules was computationally screened for hits that would bind to the ShcPTB and block its
interaction with the RTKs EGFR and ErbB2. The primary hit from the screen was indomethacin, a non-steroidal
anti-inflammatory drug. Validation of this molecule in vitro and in cellular efficacy studies in cancer cells pro-
vides proof of principle of the approach to pathway down-regulation and a potential optimizable lead com-
pound.
1. Introduction
Receptor tyrosine kinase (RTK) signalling is initiated by the binding
of an extracellular growth factor. Through a variety of RTK-related
idiosyncratic mechanisms, this event results in up-regulation of kinase
activity, auto-phosphorylation and recruitment of downstream effector
proteins to phosphorylated tyrosine residues. In normal differentiated
tissue, cells are not persistently exposed to activating concentrations of
growth factors. As a result there is the potential for redundancy of RTKs
and their associated downstream signalling proteins. Despite this these
proteins are maintained at relatively high concentration in the plasma
membrane and cytoplasm respectively. To prevent aberrant signal
transduction by the available signalling molecules the cell has to im-
pose rigorous control mechanisms. One such mechanism requires the
sequestering of a key member of the mitogen-activated kinase (MAPK)
signalling pathway, Erk (extracellular-regulated kinase), by the adaptor
protein Shc (Src homology 2-containing transforming protein). As part
of this complex Erk is prevented from being recruited to its upstream
activating kinase Mek (MAPK/Erk kinase), thus ensuring signal trans-
duction is abrogated in the absence of stimulation [1].
Shc is an adaptor protein which, despite possessing no intrinsic
catalytic activity, plays an integral part in signal transduction pathways
that are perturbed in several different cancers [2,3]. The p52 isoform of
Shc (henceforth referred to simply as Shc) comprises an N-terminal
phosphotyrosine-binding domain (PTB, henceforth referred to as
ShcPTB), a collagen homology 1 (CH1) domain and a C-terminal Src
homology 2 (SH2) domain. In stimulated cells Shc has been shown to
play a role in linking RTKs to the MAPK pathway [4–6]. Post-stimula-
tion phosphorylation of the RTK provides a phosphotyrosine (pY) re-
sidue-containing site (bearing the consensus sequence NPXpY, where X
is any amino acid [4]). Shc is recruited to this site through its PTB
domain [7–10]. Subsequent phosphorylation of tyrosine residues
(Y239. Y240 and Y317) on the CH1 domain of Shc promotes the re-
cruitment of another adaptor protein, growth factor receptor binding
protein (Grb2 [11,12]). The concomitant Shc-mediated localization of
Grb2 induces complex formation with the guanine nucleotide exchange
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factor, Sos, and represents the key initiating event in MAPK signalling.
This is followed by up-regulation of Ras and Raf and ultimately results
in the phosphorylation of Erk by Mek [13,14]. The MAPK pathway can
also be activated via direct interaction of Grb2 with RTKs followed by
recruitment of Sos. Although, this mode of pathway stimulation cir-
cumvents Shc mediation, we have previously demonstrated that the
sequestration of Erk through binding to Shc was sufficient to inhibit Erk
phosphorylation and response [1].
As the terminal kinase in the MAPK pathway, Erk plays a funda-
mental role in transducing signals from growth factor-stimulated RTKs
to induce cell growth, survival and differentiation. Prolonged phos-
phorylation of Erk results in cell proliferative signals, as a result Erk is
found upregulated in many forms of cancer, including ovarian [15],
prostate [16] and Hodgkin's disease [17]. Activated Erk functions as a
serine-threonine kinase directed towards numerous substrate proteins
[18–20]. In its activated state it also translocates to the nucleus to sti-
mulate transcription of specific genes [13,21]. Erk can also regulate the
MAPK pathway through negative feedback inhibition [22]. Further-
more, Erk is involved in cross-talk with other pathways which are
usurped in cancer [23,24]. Erk has two functionally and structurally
similar isoforms, Erk1 and Erk2 (henceforth communally referred to as
Erk).
Previously we demonstrated that Shc is a key negative regulator of
MAPK signalling in non-stimulated cells. Shc forms a complex which
sequesters Erk from involvement in MAP kinase signalling [1]. The
binding site for Erk is situated on the ShcPTB distal from the pTyr
binding site. Recruitment of Shc on RTK up-regulation results in the
adaptor protein undergoing a conformational change that releases Erk.
Free Erk is then available to be recruited, phosphorylated and hence
activated by Mek. In the context of constitutively up-regulated RTKs,
the loss of Shc regulation of Erk could be a contributing factor in ex-
acerbating oncogenic phenotypes, thus we reasoned that a molecule
that can block Shc binding to activated RTKs without triggering the
release of Erk would be beneficial in the treatment of Erk-dependent
cancers (Fig. 1A). Not only would such an inhibitor sustain the Shc-Erk
complex, but it is also anticipated that prohibition of ShcPTB binding to
the receptor would also prevent phosphorylation of tyrosine residues on
the CH1 domain and abrogate the binding of Grb2, hence blocking Ras
activation. Thus, discovery of an appropriate molecule will provide a
dual function inhibitor. This approach is validated by, for example, the
observation that disabling ShcPTB in mice can lead to delayed tumour
onset [25].
Initially an in silico docking screen was used to select small molecule
candidates directed at the ShcPTB for the inhibition of Shc-RTKs inter-
action. Our approach to this was to use an established database of
known drug compounds (DrugBank [26]) to assess whether potential
hits could provide an opportunity for repurposing. We discovered that
indomethacin, a known non-steroid anti-inflammatory drug (NSAID),
interacts with the ShcPTB directly in vitro. We employed biophysical
methods and NMR to investigate the interaction at the molecular level
and demonstrate that the indomethacin-ShcPTB interaction binds in the
canonical phosphotyrosine-binding pocket without disruption of the
Erk-binding site. We further show that in cells treated with in-
domethacin the drug competes with phosphorylated EGFR (epidermal
growth factor receptor) for binding to Shc, and in doing so is able to
down-regulate Erk signalling in a panel of cancer cell lines. This study
provides validation of the approach of inhibiting Shc binding to RTKs as
a promising therapeutic strategy as well as highlighting the possibility
of developing indomethacin-like compounds as leads to inhibit Erk
activity.
2. Materials and methods
2.1. Cheminformatics approach
The chemical structures of the approved drugs were retrieved from
the DrugBank database and prepared using the set of programs from
OpenEye Software. The fixpka tool from QUACPAC software (1.7.0.2:
OpenEye Scientific Software, Santa Fe, NM) was applied to ionize the
chemical groups at neutral pH. Then two hundred conformations were
generated with Omega (v. 3.0.0, OpenEye Software, Santa Fe, NM) for
all novel compounds (henceforth all other parameters kept as default
will not be mentioned) [27]. The NMR structure of the ShcPTB domain
(PDB code: 1SHC [7]) was chosen to dock putative novel ligands into
the pocket. The protein structure was prepared with the Make Receptor
tool for docking in the OEDocking suite (v. 3.2.0, OpenEye Software,
Santa Fe, NM) [28–30]. The box volume was 24,468 Å3 with the fol-
lowing dimensions; 26.0 Å×23.33 Å x 40.33 Å, having inner and outer
volumes of 23 Å3 and 15118 Å3 respectively. The use of the balanced
potential provided the surface around the peptide ligand binding site in
which the inner volume was positioned around the aromatic ring of the
pTyr in the structure. Two constraints were imposed due to the high
importance of the electrostatic interactions: (i) a carboxylic acid should
fit in the sphere placed on the phosphorous atom of the phosphate
group; (ii) one hydrogen bond acceptor should be pointing towards the
Arg175. The docking software FRED was applied with the Chemgauss4
scoring function to rank the compounds. Images were generated using
Chimera v. 1.12 [31] and PoseView [32] on line (http://poseview.zbh.
uni-hamburg.de/).
2.2. Cell culture
All cells were maintained in Dulbecco's modified Eagle's high glu-
cose medium (DMEM) supplemented with 10% (v/v) foetal bovine
serum (FBS) and 1% antibiotic/antimycotic (Lonza) in a humidified
incubator with 10% CO2.
2.3. Reagents
Antibodies for pErk (4695), Erk (4377), pY317 Shc (2431), pY1148
EGFR (4404), EGFR (2646), Tubulin (2144) were obtained from Cell
Signalling Technology; Shc (06–203) was from Millipore. Normal
mouse IgG (sc-2025), agarose-conjugated Shc antibody (SC-967 AC),
agarose-conjugated EGFR antibody (SC-120 AC), and protein A/G plus-
agarose (sc-2003) were from Santa Cruz Biotechnology. Recombinant
Human EGF Protein, CF (236-EG) was from R&D systems. Indomethacin
(I7378) was from Sigma-Aldrich, all indomethacin analogues were from
ChemBridge Corporation.
2.4. Cloning, expression and purification of recombinant proteins
Prokaryotic expression plasmid for ShcPTB domain has been de-
scribed previously [1]. ShcPTB R175Q was generated using site-direct
mutagenesis. Histidine-tagged fusion proteins were purified from
BL21(DE3) cells. A single colony was used to transform 100ml of LB
which was grown overnight at 37 °C. 1 L of LB were inoculated with
10mL of this overnight culture and were allowed to grow at 37 °C until
the OD600= 0.8 at which point the culture was cooled down to 20 °C
and expression was induced with 1mM IPTG. Cultures were allowed to
grow for a further 12 h before harvesting by centrifugation. Cells were
re-suspended in 20mM Tris, 150mM NaCl, 10% glycerol, pH 8.0 in the
presence of protease inhibitors and lysed by sonication. Insoluble ma-
terial was removed by centrifugation (13,000 g at 4 °C for 60min). The
soluble fraction was applied to a Talon column. Following a wash with
10 times column volume of buffer (20mM Tris, 150mM NaCl, pH 8.0)
protein was eluted from the column with 150mM imidazole and was
concentrated to 5mL and applied to a Superdex75 gel filtration column
in buffer containing 20mM HEPES, 150mM NaCl and 1mM TCEP pH
7.5. Analysis of pure proteins on SDS-PAGE showed greater than 98%
purity.
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Fig. 1. Compound identification from in silico screen of
DrugBank library. (A) Schematic of the mode-of-action of
the proposed inhibitor. Top panel: Non stimulated state. Shc
(blue oval with binding domains overlaid) binds to Erk, se-
questering it from possible recruitment by the MAPK sig-
nalling pathway. Middle panel: Stimulated state. Shc is re-
cruited by the RTK. On binding to the phosphorylated
tyrosine (green/yellow dot) Erk is released and can join the
MAPK pathway. Bottom panel: Stimulated state. The in-
hibitor (red lozenge) blocks the binding of Shc to the re-
ceptor leaving Erk bound to Shc and hence inaccessible to
MAPK signalling. (B) Superimposition of indomethacin (grey
carbons) and the phosphopeptide (pink carbons) in the PTB
binding site of Shc (green ribbons); (C) The two-dimensional
representation of the intermolecular interactions for in-
domethacin. The side chain and identification of the positive
amino acids that surround the phosphate at the pocket are
also depicted in (B). Images were generated using Chimera v.
1.12 [38] and PoseView [39] on line (http://poseview.zbh.
uni-hamburg.de/).
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2.5. Indomethacin treatment and cell lysates
Indomethacin was prepared as 1M stock in DMSO. For cell based
studies, cells were serum starved in the presence of different con-
centrations of indomethacin overnight. All cells were viable after serum
starvation, i.e. we found no evidence of cell death. 10 ng/ml EGF was
used to stimulate cells for 2 or 5min. Following PBS washing, cells were
lysed with lysis buffer containing 50mM HEPES (pH 7.5), 0.1% (v/v)
NP-40, 10mM NaF, 1mM sodium orthovanadate, 10% (v/v) glycerol,
50 mM NaCl, 1 mM PMSF and Protease Inhibitor Cocktail Set III
(Calbiochem) and required concentrations of indomethacin as in-
dicated. Cell debris was removed by centrifugation at 13,000 rpm for
20min. The detergent soluble fraction was used for western blotting or
immuneprecipitation experiments. The cells which are marked as
having zero indomethacin have only the experimental level of DMSO
added and thus act as a control for the effects of the solvent.
2.6. Immunoprecipitation and western blots
For immunoprecipitation experiments, cells were lysed with lysis
buffer as described above and 0.5 mg of whole cell lysate was prepared
in 500 μL volume. IP antibody was added to the lysate and incubated
overnight. The beads were then spun down at 4000 rpm for 3min, su-
pernatant was removed and the beads were washed with 1ml lysis
buffer. This washing procedure was repeated five times in order to re-
move non-specific binding. After the last wash, 50 μl of 2× Laemmli
sample buffer were added, the sample was boiled and subjected to SDS-
PAGE and western blot assay.
For western blotting cells were grown in 10 cm dishes, serum
starved overnight and stimulated with 10 ng/ml EGF for the indicated
time period. Cells were lysed using lysis buffer as described above. For
immunoblotting, proteins were separated by SDS-PAGE, transferred to
PVDF membranes and incubated with the specific antibodies. Immune
complexes were detected with horseradish peroxidase conjugated sec-
ondary antibodies and visualized by enhanced chemiluminescence re-
agent according to the manufacturer's instructions (Pierce).
2.7. Microscale thermophoresis (MST)
The binding affinities were measured using the Monolith NT.115
(NanoTemper Technologies, GmbH). ShcPTB was fluorescently labelled
with Atto488 according to the manufacturer's protocol. Labelling effi-
ciency was determined to be 1:1 (protein:dye) by measuring the ab-
sorbance at 280 and 488 nm. A 16 step dilution series of the unlabelled
binding partner (indomethacin) was prepared in a 2% DMSO solution,
mixed with the labelled protein at 1:1 ratio and loaded into capillaries.
Measurements were performed at 25 °C in 20mM HEPES, 150mM NaCl
and 1mM TCEP pH 7.5 buffer containing 0.01% Tween 20 and 2%
DMSO. Data analyses were performed using Nanotemper Analysis
software, v.1.2.101, and were plotted using Origin 7.0. All measure-
ments were conducted as triplicates and the errors were presented as
the standard error of the triplicates.
2.8. Isothermal titration calorimetry (ITC)
ITC experiments were carried out using a MicroCal iTC200
(Malvern) or VT ITC at 25 °C. Twenty 15 μl injections of 1400 μM in-
domethacin were made into 140 μM Shc PTB in the calorimeter cell.
Control experiments involving the injection of 1400 μM indomethacin
into buffer or buffer into 140 μM ShcPTB were performed. The heat per
injection was determined and subtracted from the binding data. Data
were analysed using a single independent site model using Origin
software.
For the ShcPTB binding to phospho-EGFR and phosphor-ErbB2
peptides experiments, twenty 2 μl injections of 500 μM peptides were
titrated into 50 μM ShcPTB. ShcPTB-indomethacin complex was prepared
by pre-incubation of 50 μM ShcPTB with 2mM indomethacin.
Indomethacin was prepared as a 1M stock solution in 100% DMSO
and diluted to desired concentration with 2% DMSO final concentra-
tion.
2.9. Nuclear magnetic resonance spectroscopy (NMR)
NMR acquisitions were carried out in the NMR buffer (20mM
HEPES, 100mM NaCl, 0.5mM TCEP and 10% (v/v) D2O) for the
190 μM 15N uniformly labelled ShcPTB. A BEST version [33,34] of amide
transverse relaxation optimized spectroscopy (TROSY) [35] pulse se-
quence was used to record amide NMR spectra. All measurements were
recorded at 25 °C on a 950MHz Brücker spectrometer equipped with a
Brücker TCI triple-resonance cryogenically cooled probe. Data was
processed with NMRPipe [36] and analysed with CcpNmr Analysis
software packages [37]. Stepwise addition of the selected drugs led to
chemical shifts for several resonances. To characterize ligand binding
chemical shift perturbation was applied. Euclidean distance moved was
calculated using formula with the scaling factor α=0.04. Calculated
distances> 0.02 ppm were considered as significant. Peak assignments
of ShcPTB backbone 15N resonances were obtained from Biological
Magnetic Resonance Data Bank (Entry ID 17080).
2.10. Wound healing assay
A431 cells were serum-starved overnight by which time confluence
reached about 80%. An artificial homogenous wound was made onto
the monolayer using an IncuCyte® 96-well WoundMaker Tool. After
wounding debris was removed by washing cells with PBS. Serum-de-
pleted medium containing 800 μM of indomethacin or the same volume
of DMSO were added to the wounded cells and 100 ng/ml of EGF ligand
was added to each well. At different time points cells that migrated into
the wounded area or cells with extended protrusions from the wound
border were photographed using IncuCyte Live-Cell Analysis.
3. Results
3.1. Identification of small molecules for Shc PTB by in silico docking
We performed an in silico screen of approved drug compounds from
the DrugBank database [27] to identify potential hits directed at the
pTyr binding site on the ShcPTB. This pocket is highly positively charged
to accommodate the tyrosyl phosphate of the cognate RTK. The avail-
able structure of pTyr bound to ShcPTB reveals that pTyr is placed the
electron-deficient pocket in ShcPTB surrounded by three basic amino
acids (Arg67, Arg175 and Lys169) which make strong electrostatic in-
teractions [7]. The computational model was built to capture the same
chemical environment to dock the drugs into the PTB domain of Shc
(Fig. 1B). The DrugBank drug compounds were evaluated to attribute
charges for the basic and acid groups at neutral pH. Before analysis,
fatty acids, amino acids, polycarboxylated compounds and compounds
with multiple charges were identified and excluded from the study.
Drugs having one carboxylic acid moiety were prioritized in the
knowledge that this chemical group is a bioisostere of the phosphate on
tyrosylphosphate-containing ligands.
The most promising drug for further studies was selected using an
approach comprising the weighted Chemgauss4 score (dividing the score
value by the molecular weight of the compound). Bearing in mind that
some molecules presented poses with almost no overlap with the native
ligand, the intermolecular interactions and pose in comparison with the
native ligand were also considered in the analyses. After an analysis of
the top scored compounds indomethacin, a known NSAID, was found to
be the best virtual hit optimizing interactions with both Arg67 and
Lys169 on the ShcPTB structure (Fig. 1C). Indomethacin sits in the heart
of the pTyr binding site with a similar intermolecular interaction pattern
that was observed for the native ligand in the target pocket.
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3.2. Indomethacin binds to the phosphotyrosine-binding pocket of the
ShcPTB domain
Both isothermal titration calorimetry (ITC) and microscale ther-
mophoresis (MST) were used to determine the affinity of the interaction
between the recombinant ShcPTB and indomethacin
(Kd= 38.2 ± 7.2 μM; Fig. 2A Kd=93.6 ± 5.6 μM; Fig. 2B respec-
tively). The unfavourable enthalpic contribution to binding (positive
ΔH; Fig. 2A) suggests that the binding of the drug is driven by the
change in entropy (ΔS) implicating the release of water molecules from
apolar surface in the binding site as an important energetic contribution
to interaction. This observation is supported by the presence of Phe202
that, in our docking model, interacts with the hydrophobic surfaces of
the indole and chlorobenzoyl groups in indomethacin (Fig. 1C). We
failed to observe binding amongst a range of indomethacin analogues
and carboxylic acid-containing compounds suggesting that the pTyr-
ShcPTB binding site exhibits some selectivity for indomethacin
(Supplementary Fig. 1).
Having shown that indomethacin and the ShcPTB interact directly,
we endeavoured to ascertain whether the interaction between
Fig. 2. Direct interaction of indomethacin and ShcPTB. (A) ITC measurement of the interaction between Indomethacin and ShcPTB. Left: Twenty 15 μl injections of
indomethacin (1400 μM) were titrated into ShcPTB (140 μM) at 25 °C. Top panel: baseline-corrected power versus time plot for the titration. Bottom panel: the
integrated heats and the molar ratio of the indomethacin to ShcPTB. Middle: the heats of dilution of 1400mM indomethacin titrated into buffer. Right: the heats of
dilution of buffer titrated into ShcPTB (140 μM). (B) Interaction of indomethacin with ShcPTB is measured using MST. Unlabelled indomethacin (2.9 μM–178 nM) was
titrated into a fixed concentration of labelled ShcPTB (50 nM).
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indomethacin and the ShcPTB is indeed via the pTyr binding pocket as
predicted in silico. Initially, 2D [1H, 15N] NMR spectroscopy was used to
identify the indomethacin binding site in the ShcPTB. This was achieved
by performing a titration of indomethacin into the ShcPTB and mea-
suring the changes in chemical shifts for 1H and 15N atoms. Chemical
shift perturbation (CSP) is the result of a change in local chemical
(caption on next page)
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environment of the atom which can be linked to the presence of a li-
gand in the complex. Stepwise addition of indomethacin led to CSPs for
several ShcPTB backbone 15N resonances. (Fig. 3A and B, Supplementary
Fig. 2). As expected for a ligand with moderate affinity the chemical
shift changes are not pronounced, however clear shifts are observable
for some atoms. Attributing these to residues in the PTB domain and
mapping these onto the structure (Fig. 3C), shows that the region that
experiences the largest perturbation includes that proximal to the pTyr
binding site incorporating Lys169 which is expected to hydrogen bond
with indomethacin (Fig. 1C). Indeed, the largest shift is seen for Gln148
which points toward the pTyr binding site. Importantly, the binding of
indomethacin appears to be located distally from the Erk binding site
suggesting that binding of the drug would not impinge on the seques-
tering of Erk by Shc (Fig. 3C). By way of comparison we analysed the
2D [1H, 15N] NMR spectral data collected for other commercially
available indomethacin-like compounds; 1-(4-fluorobenzyl)-5-
methoxy-2-methyloindole-3-acetic acid (Supplementary 3A and 3B)
and indomethacin heptyl ester (Supplementary 3C and 3D). It is clear
from the plots of CSP derived from these two compounds that the im-
pact on the ShcPTB structure is negligible. This suggests further that
within the indomethacin analogues there is selectivity for this site.
To confirm that indomethacin binds in the pTyr binding pocket we
mutated an arginine residue in the ShcPTB binding site, which is es-
sential for pTyr recognition, to the polar glutamine (Arg175Gln). The
reduction of the affinity by approximately an order of magnitude
(Kd= 590 ± 54 μM; Fig. 3D) demonstrates that indomethacin, like the
pTyr cognate ligand requires the presence of Arg175. Although Arg175
does not appear to sustain the interaction in the original screening
model, this amino acid is placed at 4.2 and 4.4 Å respectively away
from the charged groups of indomethacin. This distance falls within the
range of a salt bridge interaction and hence could stabilize the posi-
tioning of the carboxylic acid group on indomethacin.
3.3. Indomethacin competes with RTK for binding of ShcPTB
The efficacy of indomethacin as an inhibitor of binding of ShcPTB to
RTKs is dependent on its ability to compete for binding to Shc with the
tyrosyl phosphate site on the receptor. The ShcPTB has been shown to
directly interact with phosphorylated tyrosine residues on the EGFR
family RTKs EGFR (aka. ErbB1; human epidermal growth factor re-
ceptor binding protein 1) and ErbB2 upon stimulation by EGF [38–40].
ITC was used to provide a qualitative assessment of whether the binding
of cognate pTyr-containing peptides could be inhibited by the presence
of indomethacin. Peptides corresponding to the amino acid sequences
around pTyr1148 (EGFR peptide: STAVGNPEpYLNT) on EGFR, and
pTyr1122 (ErbB2 peptide: SPAFDNLYpYWDQ), a proposed binding site
on ErbB2, were synthesized and 500 μM of each was titrated into 50 μM
of ShcPTB in the absence, or the presence of 2mM indomethacin (Fig. 4A
and B). The binding of the ShcPTB to the peptides is low affinity, how-
ever the changes in observed heat measured, when compared to the
control experiment of buffer into PTB domain, reveal that binding oc-
curs. The isotherms obtained also show that when the ShcPTB is pre-
saturated with indomethacin the binding is reduced or abrogated al-
together. Using MST we could measure the binding of ShcPTB to ErbB2
pTyr1122 in the absence and presence of indomethacin. As with the ITC
experiment in the absence of the small molecule binding was observed
(Kd= 261 ± 50.7 nM), however after saturation no binding was
apparent (Fig. 4C).
3.4. Indomethacin down-regulates EGF-dependent Erk pathway in cancer
cell lines
The in vitro experimental data to date validate the in silico docking
model and demonstrate that indomethacin binds with moderate/low
affinity and occupies the pTyr-binding site within the ShcPTB. These
data also confirm that indomethacin can prevent the recruitment of
ShcPTB to activated RTKs, and hence potentially prolong the seques-
tering of Erk from MAPK signalling. To explore this we used cell-based
assays to assess how downstream signalling might be affected by the
inhibitory presence of indomethacin. A panel of cell lines which express
Shc were serum-starved overnight in the presence of indomethacin at
varying concentrations. Cells were then stimulated with 10 ng/ml EGF
for 2min. Amongst the cell lines we chose two breast cancer cell lines,
MCF7 and SkBr3, due to the strong link between Shc expression status
and breast cancer progression. We also tested carcinoma cell lines de-
rived from skin (A431), kidney (A498) and cervix (HeLa). The effects of
indomethacin on EGFR signalling were examined by immunoblotting.
In all cell lines we used, the phosphorylation of Erk upon EGF stimu-
lation was down-regulated upon indomethacin treatment (Fig. 5).
Examination of the signalling events that occur upstream of Erk
revealed two discrete mechanisms. In the first mechanism (represented
by SkBr3, Fig. 5B and A498, Fig. 5D) the MAPK pathway is up-regulated
on addition of EGF leading to phosphorylation of Mek which is in-
dependent of the concentration of indomethacin added. However, the
level of pErk is reduced in a dose-dependent way, suggesting that the
presence of the drug restricts the availability of Erk to the upstream-
activated pathway. Since the population of pShc does not change in
response to indomethacin, it is likely that an ancillary, non-receptor
tyrosine kinase is responsible for the phosphorylation of Shc. This ki-
nase is up-regulated by the EGF-activated receptor independent of Shc
recruitment, but is able to phosphorylate Y317 and hence effect the
recruitment of Grb2 to initiate MAPK signalling. A prime candidate for
this kinase is Src which has been previously shown to bind to, and
phosphorylate Shc on receptor stimulation [41,42] and is known to be
expressed in both SkBr3 and A498 cells. Indeed, ShcPTB-independent
interactions activate Src family kinases in a subset of breast cancers
[43].
In the second mechanism (MCF7, Fig. 5A; A431, Fig. 5C; and HeLa,
Fig. 5E) the levels of phosphorylation of all of the components of the
MAPK pathway (i.e. Shc, Mek and Erk) are depleted in an indomethacin
dose-dependent manner suggesting that the inhibitor is blocking
binding to the receptor in a conventional way. For example, in HeLa
cells there is a clear correlation in reduction of pShc and pErk. The
concomitant reduction in pMek confirms that the entire MAPK pathway
is being inhibited. The lack of prolonged elevation of pShc indicates
that there is no impact from ancillary kinase activity. The question as to
why the different mechanisms prevail in cell lines is likely to be the
result of differential protein expression profiles in the cells. In parti-
cular, the availability of active non-receptor tyrosine kinase in some cell
lines can impact on Shc phosphorylation and drive the MAPK pathway
through recruitment of Grb2. However, in all cases the sequestering of
Erk from the pathway down-regulates downstream signalling.
Our binding studies indicate that the affinity of indomethacin for
Fig. 3. Characterization of the indomethacin- ShcPTB interaction. (A) Sections of the 1H–15N HSQC spectra of ShcPTB showing indomethacin binding-induced
chemical shift changes. Arrows indicate the peak movement. The unbound peaks are in black and the final bound (1:20) peaks are in red. (B) Plot of the chemical shift
changes (ppm) of the backbone amide peaks of 15N-labelled ShcPTB upon addition of 1 molar equivalent of indomethacin and 10 molar equivalent of indomethacin.
(C) Chemical shift perturbations of residues (> 0.03 ppm) from plot in (B) mapped on the NMR structure of the ShcPTB (PDB code: 1SHC). The colour gradient from
salmon pink to red indicates the strength of the perturbation (ppm) of specific residues. The critical residues in the pTyr binding pockets are coloured in yellow (R67,
K169, and R175). The image shows that putative binding region with localized higher perturbation is proximal to the pTyr binding pocket. Residues in green
correspond to the Erk binding site. (D) Interaction of indomethacin with mutant ShcPTB (R175Q) measured using MST. Unlabelled indomethacin (2.9 nM–178 nM)
was titrated into a fixed concentration of labelled ShcPTB (50 nM).
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Fig. 4. Binding of indomethacin to
ShcPTB reduces the ShcPTB–
phosphotyrosine interaction. (A)
ITC measurement of the interaction
between EGFR pY1148 (EGFR peptide:
STAVGNPEpYLNT) and ShcPTB in the
absence and presence of in-
domethacin. Left: twenty 2 μl injec-
tions of EGFR pY1148 (500 μM) were
titrated into ShcPTB (50 μM) at 25 °C.
Middle: twenty 2 μl injections of EGFR
pY1148 (500 μM) were titrated into
50 μM ShcPTB pre-incubated with
2mM of Indomethacin at 25 °C. Right:
control experiment in which twenty
2 μl injections of EGFR pY1148
(500 μM) were titrated into buffer so-
lution. (B) ITC measurement of the
interaction between ErbB2 pY1122
(SPAFDNLYpYWDQ) and ShcPTB in the
absence and presence of in-
domethacin. Left: twenty 2 μl injec-
tions of ErbB2 pY1122 (500 μM) were
titrated into ShcPTB (50 μM) at 25 °C.
Middle: twenty 2 μl injections of ErbB2
pY1122 (500 μM) were titrated into
50 μM ShcPTB pre-incubated with
2mM of indomethacin at 25 °C. Right:
Control experiment in which twenty
2 μl injections of EGFR pY1114
(500 μM) were titrated into buffer so-
lution. (D) Interaction of indomethacin
with ShcPTB is measured using MST.
Unlabelled ErbB2 pY1122 (60 μM–
1.83 nM) was titrated into a fixed
concentration of labelled ShcPTB
(50 nM) (red curve). Pre-incubated
ShcPTB (50 nM) with 200 μM in-
domethacin disrupted the interaction
to ErbB2 pY1122 peptide (green
curve). (For interpretation of the re-
ferences to colour in this figure legend,
the reader is referred to the Web ver-
sion of this article.)
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Fig. 5. Indomethacin down-regulates EGF-dependent Erk1/2 pathway in cancer cell lines. The effects of indomethacin in EGFR pathway were examined by
immunoblotting. (A) MCF7, (B) SkBr3 (C) A431, (D) A498, and (E) HeLa cells were serum-starved and treated with different concentrations of indomethacin as
indicated. After EGFR stimulation cells were lysed and probed with various antibodies to examine the effect of indomethacin on the EGF-dependent pathway. The
biphasic nature of EGFR phosphorylation in HeLa cells could result from iatrogenic stress induced, ligand-independent EGFR transactivation.
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the PTB domain is significantly tighter than the effective concentration
of indomethacin used in cancer cell lines. This common observation in
inhibitor studies could result from several sources. For example, the
ability of indomethacin to penetrate different cell membranes and the
stability of indomethacin once inside the cell.
3.5. Indomethacin competes with EGFR for binding to Shc in cancer cell
lines
Finally, having shown that indomethacin inhibits the binding be-
tween Shc and EGFR in vitro and EGFR-dependent Erk phosphorylation
in different cancer cell lines, we sought to establish that the Shc-EGFR
interaction is indeed disrupted upon indomethacin treatment. We im-
munoprecipitated Shc from MCF7, Fig. 6A; SkBr3, Fig. 6B; A431,
Fig. 6C; A498, Fig. 6D; and HeLa, Fig. 6E cells in the presence and
absence of indomethacin. Also for comparison we immunoprecipitated
EGFR from A431 cells in the presence and absence of indomethacin
(Fig. 6F). The Shc-mediated complex formation was examined by im-
munoblotting. Treating cells with indomethacin is shown to apparently
block the EGFR-Shc interaction upon EGF stimulation (Fig.s 6A-F). This
confirms that indomethacin can compete with the pTyr residues on
EGFR for binding to ShcPTB.
One outcome of EGFR-mediated MAPK pathway activation is in-
creased cell motility. Therefore, to confirm the role of indomethacin in
the inhibition of Shc-mediated MAPK signalling, we performed a
wound-healing assay using A431 cells. Serum-starved A431 cells were
stimulated with 100 ng/ml EGF in the presence of 800 μM of in-
domethacin or the same volume of DMSO (Fig. 6G). The assay clearly
demonstrated that the indomethacin treatment inhibits the migratory
potential of A431 cells over the time course.
4. Discussion
The MAPK pathway is a key regulator of several important cellular
functions such as proliferation, survival and migration. Dysregulation of its
upstream components such as RTKs and the small GTPase, Ras is the
driver for a range of pathologies including cancer. Numerous studies have
focused on exploring the mechanisms of activation of MAPK signalling and
regulation to provide therapeutic approaches to block oncogenic signal
transduction. Here, we sought a fundamentally novel approach to down-
regulate MAPK signalling through inhibition of Shc-mediated activity of
Erk by identifying a small molecule inhibitor for the ShcPTB-EGFR inter-
action. In preventing Shc from binding to activated EGFR, the small mo-
lecule can have dual functionality through contributing to reduction of
pErk by two distinct mechanisms; 1) stabilising the Shc-Erk complex, and
2) preventing phosphorylation of Shc by the receptor and thus blocking
the recruitment of Grb2. In silico docking studies directed at ShcPTB re-
vealed a known NSAID, indomethacin, as the best virtual hit. In vitro
biophysical binding assays confirmed that indomethacin can interact with
ShcPTB. NMR spectroscopic analysis indicates that the binding site for in-
domethacin on PTB is located within the pTyr-binding pocket.
Importantly, we did not observe any significant chemical shifts at the Erk
binding interface upon indomethacin binding (Fig. 3C) [1]. This indicates
that binding indomethacin can block the interaction with the receptor
without perturbation of the interaction with Erk. To test our observation in
a cellular context, we treated several cancer cell lines with indomethacin
and examined its effects on MAPK signal transduction. Evidence of a re-
duction of pErk was observed which appears to be driven in specific cell
types by two distinct mechanisms of a dual function inhibitor.
While indomethacin is commonly used as an anti-inflammatory
drug through inhibiting the cyclooxygenases Cox-1 and -2, it has been
reported to show some cancer suppressive activities. Inhibition of Cox-2
was revealed to be effective in blocking angiogenesis in tumours, and
prodrugs incorporating indomethacin have been used to target cancer
cells and block vascular development [44]. Indomethacin has also been
shown to reduce cell migration [45] and invasion [46,47], properties
associated with cancer progression. Indeed indomethacin appears to be
able to interfere with calcium-dependent pathways and focal com-
plexes, which in turn, contribute to blocking cancer cell migration.
Furthermore, a number of studies have shown that indomethacin in-
hibits cell proliferation and augments apoptosis in colorectal cancer cell
lines, some of which do not express Cox-1 or -2 [48]. This indicates that
such anti-tumour effects are mediated in a Cox-independent manner, at
least in some cellular environments. Through our interdisciplinary ap-
proach, we have demonstrated that indomethacin competes with acti-
vated EGFR for the pTyr-binding pocket in the ShcPTB and in doing so is
able to reduce the levels of free Erk leading to depression of MAPK
signalling. In this way indomethacin can negatively impact on pro-
liferative outcomes from cells in tumour growth. Interestingly, EGF is a
known potent activator of Cox-2 [49], therefore the role of in-
domethacin highlighted here might also extend to down-regulation of
the tumour-associated activity of this protein.
The PTB domain from Shc has been shown to bind to other ligands
that can impinge on cancer signalling. One important example is the
phosphatase PTP-PEST which is a known binding partner of ShcPTB
[50]. Depletion of PTP-PEST in triple negative breast cancer cells leads
to hyperactivation of Erk, and its over-expression results in depho-
sphorylation of EGFR and Shc at Y317 [51]. However, the impact of this
negative-regulator of MAPK signalling is likely to be offset in the
treatment with high doses of indomethacin. Our data show that at high
dosage indomethacin can inhibit the EFGR-ShcPTB interaction which we
have shown is of the order of 100 nM. Since the interaction between
PTP-PEST is of the order of 10 μM [52] it is likely that the drug would
block this interaction at similar dosage. It is thus clear that in some cell
lines the effect of indomethacin in inhibition of negative regulators of
proliferative signalling would need to be weighed against the modus
operandi described herein.
Indomethacin binds at least 100-fold weaker than a pTyr-containing
peptide corresponding to the cognate binding site for Shc on EGFR. This
makes it unsuitable as a drug for targeting Shc. Nonetheless, our data
provide strong validation for an approach that targets the ShcPTB and
the resulting sequestering of Erk. It may also suggest the potential for
development of indomethacin as a hit compound toward lead genera-
tion.
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Fig. 6. Indomethacin competes with EGFR for binding to Shc. (A) MCF7, (B) SkBr3, (C) A431, (D) A498, and (E) HeLa cells were used to immunoprecipitate Shc
and observe the Shc-EGFR complex formation by immunoblotting. Cells were serum-starved and treated with indomethacin (MCF7: 0 μM and 800 μM, SKBR3: 0 μM
and 800 μM, A431: 0 μM and 800 μM, A498: 0 μM and 1600 μM, and Hela: 0 μM and 800 μM). After EGFR stimulation cells were lysed and probed for Shc and EGFR,
(F) A431 cells were use to immunoprecipitate EGFR and observe the EGFR-Shc complex formation by immunoblotting, and (G) Representative images and quan-
titative data of a wound healing migration assay in the presence or absence of 800 μM indomethacin for 16 and 20 h.
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